Month: September 2026

        

TARPON SPRINGS, Fla., September 15, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor—today announced that the Japan Patent Office (JPO) has granted a key patent covering Allarity’s proprietary stenoparib-specific Drug Response Predictor (DRP®) companion diagnostic. The newly granted patent, Japanese Patent No. 7917283, provides protection in Japan into 2039.

Thomas Jensen, Chief Executive Officer of Allarity Therapeutics, said: “Japan is one of the world’s largest pharmaceutical markets and is also the home of Eisai, the original developer of stenoparib. This award of the patented patent is critical to securing stenoparib’s developability in one of the world’s most important pharmaceutical markets. This award reflects our ongoing strategic efforts to strengthen and extend our intellectual property, ensuring the development and potential commercialization of stenoparib- together with its DRP® companion diagnostic- in the world’s most important commercial markets.”

The granted patent covers the DRP methods for predicting clinical benefit from stenoparib based on gene-expression profiles derived from tumor samples, as well as methods for selecting patients most likely to benefit from stenoparib treatment using the stenoparib DRP® test.

Allarity has previously secured patent protection for the stenoparib DRP® in the United States, with protection extending into April 2042, as well as in certain European jurisdictions and Australia. Related patent applications remain pending in additional international markets.

About Allarity Therapeutics

Allarity Therapeutics, Inc. (NASDAQ: ALLR) is a clinical-stage pharmaceutical company focused on developing personalized cancer treatments. The Company is developing stenoparib, a novel PARP/tankyrase inhibitor for patients with advanced ovarian cancer, and is using its proprietary DRP® technology to develop a companion diagnostic designed to identify patients expected to derive the greatest clinical benefit from stenoparib. Allarity’s principal operations are located in Denmark, and its U.S. business address is in Florida. For more information, visit www.allarity.com.

About Stenoparib/2X-121

Stenoparib is an orally available, small-molecule dual-targeted inhibitor of PARP1/2 and tankyrase 1/2. Tankyrases have emerged as potential therapeutic targets in cancer due in part to their role in regulating the WNT signaling pathway. Aberrant WNT/β-catenin signaling has been implicated in the development and progression of numerous cancers, including drug-resistant cancers. Through its inhibition of PARP and the WNT signaling pathway, stenoparib has the potential to provide therapeutic benefit across multiple cancer types, including ovarian cancer, small cell lung cancer and colorectal cancer.

Allarity has secured exclusive global rights to develop and commercialize stenoparib, which was originally developed by Eisai Co., Ltd. and was formerly known as E7449 and 2X-121.

Allarity has completed its first Phase 2 trial evaluating stenoparib in patients with advanced ovarian cancer. The trial demonstrated promising and durable clinical benefit in patients with ovarian cancer who received two or more prior lines of therapy and were treated with stenoparib twice daily. Updated data from the trial were presented at the AACR Special Conference on Advances in Ovarian Cancer in September 2025. These analyses remain subject to change as the study data mature.

Based on the emerging clinical experience with stenoparib, Allarity developed a new protocol focused on patients with platinum-resistant ovarian cancer, which began enrolling patients in the summer of 2025. The amended protocol enrolls only platinum-resistant or platinum-ineligible patients and is designed to advance the clinical development of stenoparib toward potential FDA approval.

In parallel, a separate Phase 2 trial evaluating stenoparib in combination with temozolomide for patients with relapsed small cell lung cancer, or SCLC, began enrolling in early 2026 and is currently enrolling patients at multiple U.S. Department of Veterans Affairs sites.

About the Drug Response Predictor – DRP® Companion Diagnostic

Allarity uses its drug-specific DRP® technology to identify patients who, based on the gene expression signature of their cancer, may be more likely to benefit from a particular drug. By screening patients before treatment, and selecting those with a sufficiently high, drug-specific DRP score, the DRP technology is designed to increase the likelihood of therapeutic benefit.

The DRP methodology is based on the comparisons of sensitive and resistant human cancer cell lines, and incorporates transcriptomic data, clinical tumor biology filters and prior clinical trial outcomes. The DRP uses messenger RNA expression profiles derived from patient biopsies to generate drug-specific predictive scores.

The DRP® platform has demonstrated the ability to provide statistically significant predictions of clinical outcome following drug treatment across dozens of retrospective and prospective clinical studies. The platform is designed for potential application across multiple cancer types, is patented for dozens of anti-cancer drugs and has been extensively described in peer-reviewed scientific literature.

Follow Allarity on Social Media
LinkedIn: https://www.linkedin.com/company/allaritytx/

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of applicable federal securities laws. Forward-looking statements reflect current expectations or forecasts regarding future events. The words “anticipates,” “believes,” “continues,” “could,” “estimates,” “expects,” “intends,” “may,” “might,” “plans,” “possible,” “potential,” “predicts,” “projects,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, statements regarding the term, scope, validity, enforceability and commercial value of the Company’s newly granted Japanese patent covering its stenoparib-specific DRP® companion diagnostic, including the patent’s term extending into 2039; the ability of the patent to protect the use of the stenoparib DRP® test to identify patients most likely to derive clinical benefit from stenoparib treatment; the anticipated contribution of the patent to the Company’s intellectual property and commercial strategy; the potential utility and regulatory acceptance of the DRP® companion diagnostic strategy; and the Company’s plans and ability to advance stenoparib and its companion diagnostic toward clinical development, regulatory approval and commercialization. Any forward-looking statements in this press release are based on management’s current expectations of future events and are subject to multiple risks and uncertainties that could cause actual results to differ materially from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, risks related to the scope, validity, enforceability, maintenance and interpretation of the granted Japanese patent; the possibility of third-party challenges, including during the six-month post-grant opposition period, administrative proceedings, litigation or other actions affecting the patent or the Company’s intellectual property rights; the possibility that the actual patent term or scope of protection may differ from the Company’s expectations; the Company’s ability to obtain, maintain and enforce intellectual property protection in Japan and other jurisdictions; the potential utility, clinical validation and regulatory acceptance of the DRP® companion diagnostic strategy; the Company’s ability to conduct, enroll and complete its ongoing and future clinical trials; the possibility that prior clinical observations may not be confirmed in ongoing or future studies; the ability of stenoparib to demonstrate sufficient safety, efficacy, tolerability or clinical benefit to support further development or regulatory approval; and the Company’s ability to secure sufficient financial, operational, manufacturing and clinical resources to continue development of stenoparib. For a discussion of risks and uncertainties and other important factors that could cause actual results to differ materially from those contained in the forward-looking statements, see the risk factors and other disclosures in Allarity’s filings with the SEC, including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. These filings are available through the SEC’s website. All information in this press release is as of the date of the release, and the Company undertakes no obligation to update or revise this information, except as required by applicable law.

###
Company Contact:
      investorrelations@allarity.com
        
Media Contact:
     Thomas Pedersen
     Carrotize PR & Communications
     +45 6062 9390
     tsp@carrotize.com

Attachment

• Allarity Therapeutics Granted Japanese Patent for Stenoparib DRP

NEW YORK, Sept. 15, 2026 (GLOBE NEWSWIRE) — LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing high-impact therapies that address the multiple dimensions of underserved brain disorders, today announced the appointment of Susan G. Kozauer, M.D. as Chief Medical Officer.

Dr. Kozauer is a leader in neuropsychiatric drug development with more than two decades of development expertise spanning early-stage clinical studies through regulatory approval. She brings extensive experience across indications such as schizophrenia, mood disorders, and behavioral manifestations of neurodegenerative diseases. During her tenure at Intra-Cellular Therapies, Inc., Dr. Kozauer oversaw the clinical development of multiple compounds, including the U.S. and global late-stage development of CAPLYTA (lumateperone) in adult and pediatric indications.

“Susan is a highly accomplished physician-scientist and proven drug developer whose leadership has helped bring transformative therapies to patients across both psychotic and mood disorders,” said Heather Turner, Chief Executive Officer. “We are thrilled to welcome her to LB at a pivotal moment for the company. As we advance toward topline results from our Phase 3 NOVA-2 trial in schizophrenia in the first half of 2027, Susan’s deep clinical, regulatory, and development expertise will be instrumental in shaping our development strategy and furthering our ability to deliver innovative new medicines to patients with serious neuropsychiatric disorders.”

Dr. Kozauer most recently served as Senior Vice President, Head of Clinical Development at Centessa Pharmaceuticals, a wholly owned subsidiary of Eli Lilly and Company, where she led the clinical development and strategy for its orexin agonist portfolio. Prior to that, she was Vice President, Clinical Development at Intra-Cellular Therapies, Inc., a Johnson & Johnson Company, where her work with CAPLYTA in schizophrenia, bipolar disorder, major depressive disorder, and pediatric indications resulted in multiple FDA approvals. Earlier in her career, she held clinical development roles of increasing responsibility at Premier Research and IQVIA and was also a practicing psychiatrist with special interest in treatment resistant depression. Dr. Kozauer received a Bachelor of Arts degree from Cornell University and a Doctor of Medicine from George Washington University and completed her residency in psychiatry at Georgetown University Hospital.

“I am honored to join the LB Pharmaceuticals team to lead the clinical development of LB-102, an investigational medicine that I believe has great potential to help patients across some of the most underserved neuropsychiatric disorders,” said Susan G. Kozauer, Chief Medical Officer. “I look forward to leveraging my expertise and working with the team, as we prepare for the Phase 3 NOVA-2 readout and advance LB-102 across multiple indications.”

About LB Pharmaceuticals

LB Pharmaceuticals is a neuromedicines company dedicated to developing and commercializing high-impact therapies that address the multiple dimensions of underserved brain disorders. The Company is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which the Company believes has the opportunity to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102, if approved, has the potential to become a mainstay of psychiatric practice by offering a balanced clinical activity and tolerability profile that provides a potentially attractive alternative to branded and generic therapeutics for the treatment of a broad range of neuropsychiatric diseases.

Cautionary Note Regarding Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “design,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “positioned,” “potential,” “predict,” “seek,” “should,” “target,” “will,” “would” or similar expressions are intended to identify forward-looking statements. All statements other than statements of historical facts contained in this press release are forward-looking statements. These forward-looking statements include, but are not limited to, statements concerning the therapeutic benefits of LB-102; the design, objectives, initiation, timing, progress and results of clinical trials of LB-102, including the pivotal Phase 3 NOVA-2 trial; the continuing advancement of LB-102 and the Company’s portfolio. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, among others: the Company’s limited operating history and historical losses; the Company’s ability to raise additional funding to complete the development and any commercialization of LB-102; the Company’s dependence on the success of its lead product candidate, LB-102; the Company’s ability to obtain regulatory approval of and successfully commercialize its product candidate; the early stages of clinical development of the Company’s lead product candidate, LB-102; any undesirable side effects or other properties of the Company’s product candidate; that the Company may be delayed in initiating, enrolling or completing any clinical trials; competition from third parties that are developing products for similar uses; the Company’s ability to obtain, maintain and protect its intellectual property; and the Company’s dependence on third parties in connection with manufacturing, clinical trials and preclinical studies.

These and other risks are described more fully in the section titled “Risk Factors” in the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026 and its other documents to be subsequently filed with or furnished to the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Media and Investor Contact:
Ellen Rose
erose@lbpharma.us

PALM BEACH, Fla., Sept. 15, 2026 (GLOBE NEWSWIRE) — Gabelli will host this year’s 50th Annual Automotive Symposium on November 2nd and 3rd at the Encore at Wynn in Las Vegas, Nevada. The symposium will link investors with executive leadership across the automotive value chain.

This symposium will feature presentations by senior management of leading automotive and trucking companies, with a lineup that allows investors to understand the ongoing dynamics within the automotive industry. Discussions will cover a variety of topics, including the potential effect of tariffs, vehicle affordability, car complexity and the shift to autonomous vehicles, aftermarket resilience, and more. For those who cannot attend in person, the symposium will also be available via webcast.

For additional information and to register, please visit our website. One-on-one meetings may be available upon request to Miles McQuillen at 1x1Auto@gabelli.com or (914) 921-5112.

Presenting Companies:
AutoNation, Inc. (NYSE:AN)
AutoZone, Inc. (NYSE:AZO)
Dana Incorporated (NYSE:DAN)
Donaldson Company, Inc. (NYSE:DCI)
Dorman Products, Inc. (NASDAQ:DORM)
Garrett Motion Inc. (NASDAQ:GTX)
Gentex Corporation (NASDAQ:GNTX)
Genuine Parts Company (NYSE:GPC)
Monro, Inc. (NASDAQ:MNRO)
Motorcar Parts of America, Inc. (NASDAQ:MPAA)
MP Materials Corp. (NYSE:MP)
NN, Inc. (NASDAQ:NNBR)
O’Reilly Automotive, Inc. (NASDAQ:ORLY)
Penske Automotive Group, Inc. (NYSE:PAG)
PHINIA Inc. (NYSE:PHIN)
Rush Enterprises, Inc. (NASDAQ:RUSHA)
Sonic Automotive (NYSE:SAH)
Standard Motor Products, Inc. (NYSE:SMP)
Strattec Security Corporation (NASDAQ:STRT)
Additional participants and a detailed agenda will be announced

Click here to register for the 50^th Annual Automotive Symposium or scan the QR code.

Contact

Miles McQuillen
P: 914-921-5112
E: mmcquillen@gabelli.com

Gabelli Funds, LLC is a registered investment adviser with the Securities and Exchange Commission and is a wholly owned subsidiary of GAMCO Investors, Inc.

Contact:

Miles McQuillen
(914) 921-5112

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/c115d0a9-2206-4ef3-8356-9d92b6d3bde8

Biodexa Enters Into Warrant Exercise Transaction for $2.3 Million in Gross Proceeds

September 15, 2026

Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX) (“Biodexa” or the “Company”), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announced that it has entered into a warrant exercise agreement with an existing accredited investor to exercise certain outstanding warrants to purchase an aggregate of 2,204,218 American Depositary Shares (“ADSs”) of the Company (the “Existing Warrants”) at an exercise price of $1.05 for gross cash proceeds of approximately $2.3 million, before deducting financial advisor fees and other transaction expenses. The ADSs issuable upon the exercise of the existing warrants have been registered pursuant to an effective registration statement on Form F-1, as amended (File No. 333-297473).

In consideration for the immediate exercise of the Existing Warrants for cash, the exercising holder will receive new unregistered warrants to purchase an aggregate of up to 4,408,436 ADSs (the “New Warrants”). The New Warrants will have an exercise price of $1.05, will be immediately exercisable upon issuance, and will have a term of exercise of five (5) years. The closing of the warrant inducement transaction is expected to occur on or about September 15, 2026, subject to satisfaction of customary closing conditions.

Maxim Group LLC acted as warrant inducement agent and financial advisor in connection with the transaction.

The New Warrants described above were offered in a private placement pursuant to an applicable exemption from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”) and, along with the ADSs issuable upon their exercise, have not been registered under the Securities Act, and may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from such registration requirements. The New Warrants were offered only to accredited investors. The Company has agreed to file a registration statement with the U.S. Securities and Exchange Commission covering the resale of the ADSs issuable upon exercise of the New Warrants.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Biodexa Pharmaceuticals PLC

The Company’s lead development programs include eRapa, under development for Familial Adenomatous Polyposis and Non-Muscle Invasive Bladder Cancer, MTX240 under development for Gastrointestinal Stromal Tumors (GIST) and tolimidone, under development for the treatment of type 1 diabetes.

eRapa is a proprietary oral capsule formulation of rapamycin, also known as sirolimus. Rapamycin is an mTOR (mammalian Target Of Rapamycin) inhibitor. mTOR has been shown to have a significant role in the signalling pathway that regulates cellular metabolism, growth and proliferation and is activated during tumorigenesis.

MTX240 is a molecular glue, bringing two intracellular proteins, PDE3a and SLFN12, specifically co-expressed by GIST cancer cells, into close proximity to form a stable complex. This interaction stabilizes SLFN12, enabling it to drive RNase-mediated apoptosis in GIST cells through a mechanism independent of KIT signalling.

Tolimidone is an orally delivered, potent and selective inhibitor of Lyn kinase. Lyn is a member of the Src family of protein tyrosine kinases, which is mainly expressed in hematopoietic cells, in neural tissues, liver, and adipose tissue. Tolimidone demonstrates glycaemic control via insulin sensitization in animal models of diabetes and has the potential to become a first in class blood glucose modulating agent.

Biodexa’s headquarters and R&D facility is in Cardiff, UK. For more information visit www.biodexapharma.com.

Forward Looking Statements

Certain statements in this announcement may constitute “forward-looking statements” within the meaning of legislation in the United Kingdom and/or United States.  Such statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and are based on management’s belief or interpretation.  All statements contained in this announcement that do not relate to matters of historical fact should be considered forward-looking statements including. In certain cases, forward-looking statements can be identified by the use of words such as “plans”, “expects” or “does not anticipate”, or “believes”, “intends”, “potential”, “under development”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved.”  Forward-looking statements and information are subject to various known and unknown risks and uncertainties, many of which are beyond the ability of the Company to control or predict, that may cause their actual results, performance or achievements to be materially different from those expressed or implied thereby, and are developed based on assumptions about such risks, uncertainties and other factors set out herein.

Reference should also be made to the risk factors described in the Company’s most recent annual report filed with the SEC, and to those documents that Biodexa shall file from time to time or announcements that may be made by Biodexa in accordance with the rules and regulations promulgated by the SEC, which contain and identify other important factors that could cause actual results to differ materially from those contained in any projections or forward-looking statements.  These forward-looking statements speak only as of the date of this announcement.  All subsequent written and oral forward-looking statements by or concerning Biodexa are expressly qualified in their entirety by the cautionary statements above.  Except as may be required under relevant laws in the United States, Biodexa does not undertake any obligation to publicly update or revise any forward-looking statements because of new information, future events or events otherwise arising.

For more information, please contact:

Biodexa Pharmaceuticals PLC

Stephen Stamp, CEO, CFO

Tel: +44 (0)29 20480 180

www.biodexapharma.com

NEW YORK, Sept. 15, 2026 (GLOBE NEWSWIRE) — Baird Medical Investment Holdings Limited (“Baird Medical” or the “Company”) (Nasdaq: BDMD), a global medical technology company focused on the development and commercialization of minimally invasive treatment solutions, today announced that management will present at the H.C. Wainwright 28th Annual Global Investment Conference in New York City.

H.C. Wainwright 28th Annual Global Investment Conference
Date: Wednesday, September 16, 2026
Time: 11:30 a.m. ET
Location: Lotte New York Palace Hotel, New York City

A live webcast of the presentation will be available through the Investor Relations section of Baird Medical’s website, and a replay will be accessible following the event.

To register for the live webcast and access the replay, please visit: https://journey.ct.events/view/301b33c3-64a0-48ea-95a6-cc7ead3ef078

Baird Medical US CEO and CSO, Mark Saxton and Daphne Huang, will be hosting one-on-one meetings with institutional investors throughout the three-day conference. Investors interested in meeting with Baird Medical’s leadership team during or around the conference are encouraged to contact H.C. Wainwright at meetings@hcwco.com and IR representative, Lee Roth, at Burns McClellan, lroth@burnsmc.com.

About Baird Medical

Baird Medical is a global, pioneering medical device company specializing in minimally invasive ablation technologies for a range of solid tumors. The Company’s lead product, a microwave ablation (MWA) system, is FDA-cleared for soft tissue ablation and is being launched in the U.S. primarily for the treatment of benign thyroid nodules. In addition, the Company is expanding its minimally invasive technology portfolio, including IRE-based products and an AI-powered robotic ablation system.

Baird Medical’s MWA solutions have been adopted by a growing number of leading U.S. institutions and private practice groups, including the Mayo Clinic, Columbia University Medical Center, and The George Washington University Hospital. The company is rapidly expanding its global commercial footprint, with sales now reaching markets across multiple continents.

Forward-Looking Statements

This press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or Baird Medical’s future financial or operating performance. In some cases, you can identify forward-looking statements by terminology such as “may”, “could”, “should”, “expect”, “intend”, “might”, “will”, “estimate”, “anticipate”, “believe”, “budget”, “forecast”, “intend”, “plan”, “potential”, “predict”, or “continue”, or the negatives of these terms or variations of them or similar terminology. Forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Baird Medical and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Baird Medical does not undertake any duty to update these forward-looking statements.

Actual results may vary materially from those expressed or implied by forward-looking statements based on a number of factors, including, without limitation: (1) the risk that Baird Medical may not be successful in expanding its business in China or the United States; (2) changes in general economic conditions; (3) regulatory conditions and developments; (4) changes in applicable laws or regulations; (5) the nature, cost and outcome of pending and future litigation and other legal proceedings instituted against Baird Medical or others; and (6) other risks and uncertainties from time to time described in the Registration Statement relating to the Business Combination and the transition report, including those listed under the sections titled “Risk Factors” therein, and in ExcelFin’s other filings with the SEC.

The foregoing list of factors is not exclusive. Additional information concerning certain of these, and other risk factors is contained in ExcelFin’s most recent filings with the SEC and in the Registration Statement described above filed by Baird Medical in connection with its business combination with ExcelFin. All subsequent written and oral forward-looking statements concerning Baird Medical, the business combination described herein, or other matters attributable to Baird Medical or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Baird Medical expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

TORONTO, Sept. 15, 2026 (GLOBE NEWSWIRE) — Quantum BioPharma Ltd. (NASDAQ: QNTM) (FSE: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development, announces is pleased to announce its participation in the upcoming 3rd Annual ArcStone-Kingswood Growth Summit in Toronto, taking place on September 16, 2026, at the Sheraton Center Toronto Hotel. Anthony Durkacz, Co-founder and Executive Co-chairman of the board of Quantum BioPharma, will be presenting on the company’s recent milestones and future growth strategy.

Recently Quantum BioPharma announced that the U.S. Food and Drug Administration (FDA) had approved its Investigational New Drug application for Lucid-MS, to begin Phase 2 trials for the very first time to advance its patented, first-in-class multiple sclerosis (“MS”) program in patients with progressive MS. This is currently an area of substantial unmet medical need within a global MS therapeutics market anticipated to reach approximately US$38.62 billion by 2030 (Grand View Research, 2026).

Lucid-MS is a patented, new chemical entity investigational drug candidate designed to provide neuroprotection through the inhibition of demyelination, a key contributor to disability progression in multiple sclerosis. Unlike most existing therapies that focus primarily on modulating the immune system, Lucid-MS represents a differentiated approach targeting the underlying neurodegeneration—a novel mechanism with the potential to address the root cause of disease advancement in progressive MS.

The ArcStone-Kingswood Growth Summit will be hosting growth issuers and a curated group of investors, family offices, institutional investors, capital market professionals and service providers for a full day of company presentations, networking and 1-on-1 meetings.

Alongside the curated program of 1:1 meetings connecting investors with appropriate projects, the conference program will provide keynote presentation, panel discussions and conversations on the industry developments.

Interested investors who would like to attend the ArcStone-Kingswood Growth Summit can register for a free pass here.

“We’re excited to present Quantum BioPharma to such a large group of potential investors,” said Mr. Durkacz, Co-founder and Executive Co-chairman of the board of Quantum BioPharma.

About ArcStone Securities and Investments Corp.

ArcStone Securities and Investments Corp. is a diversified financial services firm with offices in New York and Toronto. Our firm specializes in providing bespoke solutions to mid-market companies worldwide, with a particular focus on cross-border transactions between Canada and the United States. Our partnership with Kingswood US enhances our ability to offer a full spectrum of financial services to our clients.

About Kingswood US

Kingswood US is a mid-market investment bank with a strong retail equity capital markets franchise and deep rooted investment bank. The firm is dedicated to providing comprehensive financial services, including investment banking, wealth management, and capital raising, to clients across the United States.

About Quantum BioPharma Ltd.

Quantum is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (“Lucid”), Quantum is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum invented UNBUZZD™ and spun out its OTC version to a company, Unbuzzd Wellness Inc. (“Unbuzzd”) (formerly, Celly Nutrition Corp.), led by industry veterans. Quantum retains ownership of 19.48% (as of June 30, 2026) of Unbuzzd. The agreement with Unbuzzd also includes royalty payments of 7% of sales from unbuzzd™ until payments to Quantum total $250 million. Once $250 million is reached, the royalty drops to 3% in perpetuity. Quantum retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses.

Forward-Looking Information

This press release contains certain “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of applicable securities law. Any statements that are not statements of historical fact may constitute forward-looking statements. Forward-looking statements are often, but not always, identified by words or phrases such as “believes,” “anticipates,” “expects,” “estimates,” “intends,” “plans,” “forecasts,” “targets,” “hopes,” “may,” “could,” “would,” “will,” “should,” “might” and similar expressions.

Forward-looking statements in this press release include, but are not limited to, statements regarding the Company’s participation in the ArcStone-Kingswood Growth Summit; the anticipated presentation by Anthony Durkacz regarding the Company’s recent milestones and future growth strategy; the Company’s participation in investor meetings and networking activities; the Company’s business plans, objectives and future growth strategy; and the potential opportunities or benefits that may arise from the Company’s participation in the Summit.

Forward-looking statements are based on a number of material factors and assumptions that management believes are reasonable as of the date of this press release, including assumptions regarding the Company’s ability to participate in the Summit as planned; the availability of management and other participants; the Company’s ability to execute its business and development strategies; its ability to obtain sufficient financing on acceptable terms when required; and general economic, market, regulatory and industry conditions. Although the Company considers these assumptions reasonable, they may prove to be incorrect.

Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements. These risks and uncertainties include, among others, changes to or cancellation of the Summit or the Company’s participation in it; the possibility that investor meetings, presentations or networking activities do not result in anticipated opportunities or benefits; changes in the Company’s business plans or strategy; the Company’s ability to obtain financing and maintain adequate liquidity; risks inherent in the development and commercialization of pharmaceutical and biotechnology products; regulatory and clinical development risks; market and competitive conditions; and the other risk factors identified in the Company’s continuous disclosure filings.

The reader is urged to refer to the additional information relating to Quantum BioPharma, including the risk factors described in its most recent annual report and management’s discussion and analysis, available on SEDAR+ and in the Company’s filings with the U.S. Securities and Exchange Commission through EDGAR, for a more complete discussion of such risk factors and their potential effects.

This list of risk factors should not be construed as exhaustive. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any obligation to publicly update or revise any forward-looking statements or information contained herein, except as required by applicable securities laws. The forward-looking statements contained in this document are expressly qualified by this cautionary statement.

Contacts:

Quantum BioPharma Ltd.
Zeeshan Saeed, Founder, CEO and Executive Co-Chairman of the Board
Email: Zsaeed@quantumbiopharma.com
Telephone: (833) 304-0323

Investor Relations
Investor Relations: IR@QuantumBioPharma.com
General Inquiries: info@QuantumBioPharma.com

Kaltura’s offers end-to-end AI capabilities across the video life cycle, deep integration into enterprise workflows, and Agentic Avatars and Genies that turn video into interactive, actionable knowledge

New York, New York, Sept. 15, 2026 (GLOBE NEWSWIRE) — Kaltura (Nasdaq: KLTR), the Agentic Digital Experience company, today announced that Gartner has named Kaltura the Company to Beat in its latest analysis of the AI race in Video Platform Services AI.

The new report, AI Vendor Race: Kaltura is the Company to Beat for Video Platform Services AI, identifies Kaltura as the current front-runner in a rapidly evolving market where AI is transforming video from content that organizations primarily host and watch into knowledge they can search, interact with, and act upon.

We believe, this recognition marks a notable shift in the competitive landscape. In its August 2026 analysis, Gartner states that Kaltura is now at the forefront, pointing to the breadth of its AI capabilities across video production, management and delivery, and its focus on productivity, engagement and accessibility.

Kaltura’s provides coverage of the complete video life cycle – spanning creation, editing, streaming, management, moderation and analytics – with AI integrated throughout. Kaltura’s ability to integrate AI into existing enterprise automation and transform video libraries into searchable and actionable knowledge, rather than treating AI as a standalone feature or limiting it to capabilities such as transcription and translation is noteworthy.

Kaltura’s Agentic Avatars and Genies are central to that approach. Rather than simply generating videos or having avatars narrate scripted text, Kaltura’s agents can interpret context, draw on approved organizational knowledge, operate within enterprise guardrails and interact with users in real time. Combined with governance, SDKs, APIs and multimodal context, they enable organizations to turn existing and newly created content into interactive experiences for employees, customers, learners and audiences.

“Enterprises have spent years pouring some of their most valuable knowledge into video, and most of that knowledge still sits idle,” said Ron Yekutiel, Co-Founder, Chairman, President and Chief Executive Officer of Kaltura. “We believe the next chapter of video is not about watching more of it. It is about making video intelligent and agentic – able to understand, converse, personalize and act. We hold the view that Gartner naming Kaltura the Company to Beat is powerful validation of the direction we have been pursuing: turning video and digital experiences into an active intelligence layer for every organization.”

Kaltura believes its combination of enterprise-grade video infrastructure, content intelligence, conversational AI and real-time agents positions it strongly as these markets converge.

“We built AI into the video stack, not alongside it,” said Eynav (Navi) Azaria, Chief Product and Engineering Officer at Kaltura. “That means AI can create and transform content, understand what is inside it, govern and moderate it, connect it to enterprise systems, and turn it into an experience people can converse with. The opportunity now is to make all of that intelligence available programmatically to enterprises and to the AI agents they increasingly rely on.”

We think, this recognition follows a year of continued expansion of Kaltura’s AI portfolio, including its Avatar Video Production Studio, Avatar-Powered Roleplay for enterprise learning and training, and advances in real-time emotional intelligence for Agentic Avatars. Kaltura and PathFactory, a Kaltura company, have also received recent recognition from Forrester, IDC, ISG Research, Frost & Sullivan and Aragon Research across conversational AI, enterprise video, virtual events and related digital experience markets.

Gartner Report, AI Vendor Race: Kaltura Is the Company to Beat for Video Platform Services AI, By Amol Nerlekar, Forest Conner, August 2026.

Gartner Disclaimer

GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and is used herein with permission. All rights reserved. Gartner does not endorse any company, vendor, product or service depicted in its publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner publications consist of the opinions of Gartner’s business and technology insights organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this publication, including any warranties of merchantability or fitness for a particular purpose.

About Kaltura  

Kaltura’s mission is to power rich, agentic digital experiences across organizational journeys for customers, employees, learners, and audiences. Its platform combines intelligent content creation, enterprise-grade content management and intelligence, and multimodal conversational engagement capabilities. Kaltura serves leading enterprises, financial institutions, educational institutions, media and telecom providers, and other organizations worldwide. For more information, visit www.kaltura.com.  

CONTACT: Nohar Zmora  
SVP, Head of Marketing 
pr.team@kaltura.com  

Recognition underscores Cass’s leadership in parcel spend management and transportation financial operations

ST. LOUIS, Sept. 15, 2026 (GLOBE NEWSWIRE) — Cass Information Systems, Inc. (Nasdaq: CASS) has been named a 2026-27 Hot Company by PARCEL, a leading media source covering the small-package supply chain industry. Cass was recognized among a select group of solution providers featured in PARCEL’s annual Hot Companies issue.

“Being recognized by PARCEL validates the value we deliver to high-volume shippers navigating an increasingly complex parcel environment,” said Tony Urban, President – Transportation Information Services. “Carrier pricing changes, new surcharge structures, evolving service offerings, and increasing cost pressures make parcel management more challenging than ever. Cass helps organizations gain control, improve financial accuracy, and make better decisions with confidence.”

Cass helps organizations manage parcel shipping costs through a comprehensive parcel spend management solution that includes invoice auditing, carrier performance analysis, service claims management, reporting, cost allocations, accrual support, and carrier payments. By combining advanced analytics with a robust payment infrastructure, Cass helps shippers improve visibility, strengthen financial controls, and optimize transportation spend.

Organizations use Cass to:

• Improve financial accuracy across parcel operations
• Identify savings opportunities and reduce unnecessary costs
• Recover eligible claims and billing discrepancies
• Strengthen carrier negotiations with better data and reporting
• Gain deeper visibility into shipping activity and cost drivers
• Ensure charges are validated, allocated, paid, and reported consistently

For more than 70 years, Cass has supported large and complex shippers with transportation financial management solutions that deliver both operational insight and financial confidence. As a publicly traded financial holding company, Cass applies rigorous controls and accountability to transportation spend management, helping organizations trust the data behind their decisions.

“Parcel spend management requires more than visibility alone,” Urban added. “Organizations also need confidence in the financial process. Data creates visibility. Financial integrity creates confidence. The world’s largest shippers choose Cass because they need both.”

Organizations seeking to improve parcel visibility, optimize costs, and strengthen financial controls can learn more at cassinfo.com/parcel.

The complete list of 2026-27 Hot Companies is available in PARCEL’s annual Hot Companies issue.

About Cass Information Systems

Cass Information Systems, Inc. is a leading provider of integrated information and payment management solutions. Cass enables enterprises to achieve visibility, control and efficiency in their supply chains, communications networks, facilities and other operations. Disbursing over $94 billion annually on behalf of clients, and with total assets of $2.5 billion, Cass is uniquely supported by Cass Commercial Bank. Founded in 1906 and a wholly owned subsidiary, Cass Commercial Bank provides sophisticated financial exchange services to the parent organization and its clients. Cass is part of the Russell 2000^®. More information is available at www.cassinfo.com.

Media Contact:
Melia Cothran
Cass Information Systems, Inc.
314.640.1754
mcothran@cassinfo.com

Records second consecutive quarter of overall growth with FYQ2 consolidated net revenues up 1.1% to $71.6 million
Direct Segment sales accelerated versus Q1 up 8.0%
Reiterates FY 2027 Sales and Operating Margin Guidance

FORT WAYNE, Ind., Sept. 15, 2026 (GLOBE NEWSWIRE) — Vera Bradley, Inc. (Nasdaq: VRA) (the “Company”) today announced its financial results for the second quarter of the fiscal year ending January 30, 2027 (“Fiscal 2027”).

Second Quarter Comments
“I’m pleased to report that our second quarter results reflect continued momentum in our transformation,” said Ian Bickley, Chairman and Chief Executive Officer of Vera Bradley. “This marked our second consecutive quarter of overall revenue growth, with total revenue up 1.1% versus the prior year. The underlying health of our business continued to strengthen across our direct channels, margin structure, and balance sheet.”

Bickley continued, “Our direct segment delivered revenue growth of 8%, our fifth consecutive quarter of sequential improvement, with comparable sales up 9.2% for the quarter, our second consecutive quarter of positive comparable results. Momentum built as the back-to-school season took hold during the second quarter and we entered the third quarter with strength across both our full-price and outlet channels.”

“We continued to manage our balance sheet and liquidity with discipline. Inventory ended the quarter down 28% compared to last year, in the quarter we generated $23 million of operating cash flow and we closed the quarter with $34 million of cash, double our prior-year position, and no debt.”

“Based on our year-to-date performance, we continue to expect year-over-year non-GAAP operating loss improvement of at least 50%. Significant work remains, and we’re encouraged by the progress we’re seeing across all five pillars of our transformation, and we remain committed to returning the business to long-term sustainable growth, profitability, and cash flow generation,” concluded Bickley.

Summary of Financial Performance for the Second Quarter
Consolidated net revenues from continuing operations totaled $71.6 million, compared to $70.9 million in the prior year second quarter ended August 2, 2025.

Vera Bradley, Inc.’s net income from continuing operations totaled $4.5 million, or $0.15 per diluted share. On a non-GAAP basis, net income from continuing operations totaled $3.3 million, or $0.11 per diluted share.

In the prior year second quarter, net loss from continuing operations totaled ($4.7) million, or ($0.17) per diluted share. On a non-GAAP basis, net loss from continuing operations totaled ($0.5) million, or ($0.02) per diluted share.

Second Quarter Details
Direct segment revenues totaled $65.4 million, an 8.0% increase from $60.5 million in the prior year second quarter. Comparable sales increased 9.2%, with all channels positive, driven by improved ecommerce conversion and improved average transaction value across direct channels.

Indirect segment revenues totaled $6.3 million, a 39.4% decrease from $10.3 million in the prior year second quarter. The decrease was driven by strategic shifts and timing related to our marketplace strategy, in addition to a reduction in liquidation sales, while continued improvements in specialty and department stores partially offset this decline.

Consolidated gross profit totaled $42.8 million, or 59.8% of net revenues, compared to $35.5 million, or 50.1% of net revenues, in the prior year. On a non-GAAP basis, prior year consolidated gross profit totaled $35.4 million, or 49.9% of net revenues. The increase in year-over-year margin rate is primarily due to the impact of $7.7 million for tariff refunds received during the quarter relating to prior period customs entries; excluding tariff refunds gross margin rate improved more than 0.4% versus last year.

Consolidated selling, general, and administrative (“SG&A”) expense totaled $38.7 million, or 54.1% of net revenues, compared to $40.4 million, or 57.1% of net revenues, in the prior year. On a non-GAAP basis, consolidated SG&A expense totaled $38.7 million, or 54.0% of net revenues, compared to $36.3 million, or 51.2% of net revenues, in the prior year. The increase in non-GAAP SG&A expense is due to higher variable compensation expense this year combined with prior year benefit from stock forfeitures.

Operating income from continuing operations totaled $4.2 million, or 5.8% of net revenues, compared to an operating loss of ($4.6) million, or (6.5%) of net revenues, in the prior year second quarter – a 1230 basis point improvement. On a non-GAAP basis, operating income (loss) from continuing operations totaled $4.3 million, or 5.9% of net revenues, compared to ($0.6) million, or (0.8%) of net revenues, in the prior year second quarter – a 670 basis point improvement.

By segment:

• Direct operating income was $16.7 million, or 25.5% of Direct net revenues, compared to $9.3 million, or 15.4% of Direct net revenues, in the prior year.
• Indirect operating income was $3.0 million, or 47.5% of Indirect net revenues, compared to $2.2 million, or 21.2% of Indirect net revenues, in the prior year.
• On a non-GAAP basis, the above segment results do not significantly change.

Balance Sheet
Cash and cash equivalents as of August 1, 2026, totaled $34.2 million compared to $15.2 million at the end of last year’s second quarter and up $15.7 million versus the January 31, 2026 fiscal year end. The Company had no borrowings on its asset-based lending (“ABL”) facility during the quarter.

As of August 1, 2026 inventory was $69.3 million, a 28.4% reduction, compared to $96.7 million at the end of last year’s second quarter. The decrease is driven by improved assortment planning, buy management, and sales performance, as well as the $5.3 million Project Restoration inventory reserve.

Year to date net capital spending has totaled $1.0 million compared to $2.6 million in the prior year and was driven by store relocations that occurred in the prior year period.

Fiscal Year 2027 Guidance
Excluding net revenues, all guidance-related numbers are non-GAAP. The prior year income statement numbers used in the forward-looking discussion below are also non-GAAP. Non-GAAP adjustments are discussed in the Non-GAAP Numbers section, below.

• The Company continues to focus on stabilizing the business and plans for sales to be in the range of $255 million to $270 million.
• The guided sales range reflects the impact of rebuilding of the wholesale business under new leadership, while also placing less emphasis on liquidation channels.
• Due to continued operational focus, the Company anticipates improvements in gross profit and SG&A rates, enabling operating loss improvement by 50% or better versus the prior year loss of ($21.7) million.

Disclosure Regarding Non-GAAP Measures

Non-GAAP Numbers
The current-year non-GAAP second quarter and six-month income statement amounts referenced below exclude the previously outlined charges for severance, consulting and professional fees associated with strategic initiatives and shareholder matters, professional fees associated with the sale of Pura Vida, transformation initiatives, and the income tax effect related to these items.

The prior-year non-GAAP second quarter and six-month income statement amounts referenced below exclude the previously outlined charges for severance, consulting and professional fees associated with strategic initiatives and shareholder matters, property, plant and equipment impairment charges, professional fees associated with the sale of Pura Vida, PO cancellation fees, transformation initiatives, inventory write-offs associated with the sale of Pura Vida, and the income tax effect related to these items.

The Company’s management does not, nor does it suggest that investors should, consider the supplemental non-GAAP financial measures in isolation from, or as a substitute for, financial information prepared in accordance with accounting principles generally accepted in the United States (“GAAP”). Further, the non-GAAP measures utilized by the Company may be unique to the Company, as they may be different from non-GAAP measures used by other companies.

The Company believes that the non-GAAP measures presented in this earnings release, including cash usage; gross profit; selling, general, and administrative expenses; operating loss from continuing operations; net loss from continuing operations; and diluted net loss from continuing operations per share, along with the associated percentages of net revenues, are helpful to investors because they allow for a more direct comparison of the Company’s year-over-year performance and are consistent with management’s evaluation of business performance. A reconciliation of the non-GAAP measures to the most directly comparable GAAP measures can be found in the Company’s supplemental schedules included in this earnings release.

Consistent with SEC regulations, the Company has not provided a reconciliation of forward-looking non-GAAP financial measures to the most directly comparable GAAP financial measures in reliance on the “unreasonable efforts” exception set forth in the applicable regulations, because there is substantial uncertainty associated with predicting any future adjustments the Company may make to its GAAP financial measures in calculating non-GAAP financial measures.

Call Information
A conference call to discuss the second quarter financial results is scheduled for today, Tuesday, September 15, 2026, at 8:30 a.m. Eastern Time. A live webcast of the conference call will be available on the Company’s website, Investor Relations | Vera Bradley Designs Inc. Alternatively, interested parties may dial into the call at (877) 407-0779. A replay will be available shortly after the conclusion of the call and remain available through September 29, 2026. To access the recording, listeners should dial (844) 512-2921 and enter the access code 13761527.

About Vera Bradley, Inc.
Vera Bradley, based in Fort Wayne, Indiana, is a leading designer of women’s handbags, luggage and other travel items, fashion and home accessories, and unique gifts. Founded in 1982 by friends Barbara Bradley Baekgaard and Patricia R. Miller, the brand is known for its innovative designs, iconic patterns, and brilliant colors that inspire and connect women unlike any other brand in the global marketplace.

The Company has two reportable segments: Direct and Indirect. The Direct business consists of sales of products through Vera Bradley Full-Line and Outlet stores in the United States; Vera Bradley’s websites, www.verabradley.com, www.verabradleyoutlet.com, and international.verabradley.com; direct to consumer marketplaces; and typically (but not in fiscal 2027), the Vera Bradley annual outlet sale in Fort Wayne, Indiana. The Indirect business consists of sales of Vera Bradley products to approximately 1,200 specialty retail locations throughout the United States, as well as select department stores, national accounts, and third-party inventory liquidators; and royalties recognized through licensing agreements related to the Vera Bradley brand.

Website Information
We routinely post important information for investors on our website www.verabradley.com in the “Investor Relations” section. We intend to use this webpage as a means of disclosing material, non-public information and for complying with our disclosure obligations under Regulation FD. Accordingly, investors should monitor the Investor Relations section of our website, in addition to following our press releases, SEC filings, public conference calls, presentations and webcasts. The information contained on, or that may be accessed through, our webpage is not incorporated by reference into, and is not a part of, this document.

Investors and other interested parties may also access the Company’s most recent Corporate Responsibility and Sustainability Report outlining its ESG (Environmental, Social, and Governance) initiatives at https://verabradley.com/pages/corporate-responsibility. 

Vera Bradley Safe Harbor Statement
Certain statements in this release are “forward-looking statements” made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements reflect the Company’s current expectations or beliefs concerning future events and are subject to various risks and uncertainties that may cause actual results to differ materially from those that we expected, including: possible adverse changes in general economic conditions and their impact on consumer confidence and spending; possible inability to predict and respond in a timely manner to changes in consumer demand; possible loss of key management or design associates or inability to attract and retain the talent required for our business; possible inability to maintain and enhance our brands; possible inability to successfully implement the Company’s long-term strategic plan; possible inability to successfully open new stores, close targeted stores, and/or operate current stores as planned; incremental tariffs or adverse changes in the cost of raw materials and labor used to manufacture our products; possible adverse effects resulting from a significant disruption in our distribution facilities; or business disruption caused by pandemics or other macro factors. More information on potential factors that could affect the Company’s financial results is included from time to time in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s public reports filed with the SEC, including the Company’s Form 10-K for the fiscal year ended January 31, 2026. We undertake no obligation to publicly update or revise any forward-looking statement. Financial schedules are attached to this release.

Vera Bradley, Inc. Condensed Consolidated Balance Sheets (in thousands)
(unaudited)
		August 1, 2026			January 31, 2026			August 2, 2025
Assets
Current assets:
Cash and cash equivalents		$	34,249		$	18,513		$	15,184
Accounts receivable, net			12,819			17,301			16,983
Inventories			69,252			75,951			96,685
Short-term contingent consideration			1,835			1,605			1,694
Income taxes receivable			223			317			444
Prepaid expenses and other current assets			7,468			6,034			9,463
Total current assets			125,846			119,721			140,453
Operating right-of-use assets			64,915			63,233			66,876
Property, plant, and equipment, net			44,255			46,358			49,357
Long-term contingent consideration			—			230			858
Other assets			4,257			4,463			8,632
Total assets		$	239,273		$	234,005		$	266,176
Liabilities and Shareholders’ Equity
Current liabilities:
Accounts payable		$	14,905		$	16,235		$	21,127
Accrued employment costs			8,698			5,394			7,242
Short-term operating lease liabilities			15,573			18,620			17,814
Other accrued liabilities			12,353			10,185			11,541
Income taxes payable			22			16			—
Total current liabilities			51,551			50,450			57,724
Long-term debt			—			—			10,000
Long-term operating lease liabilities			55,395			51,914			57,919
Other long-term liabilities			2			2			47
Total liabilities			106,948			102,366			125,690
Shareholders’ equity:
Additional paid-in-capital			117,180			116,152			115,286
Retained earnings			172,114			172,439			182,147
Accumulated other comprehensive loss			(149	)		(132	)		(127	)
Treasury stock			(156,820	)		(156,820	)		(156,820	)
Total shareholders’ equity			132,325			131,639			140,486
Total liabilities and shareholders’ equity		$	239,273		$	234,005		$	266,176

Vera Bradley, Inc. Condensed Consolidated Statements of Operations (in thousands, except per share amounts)
(unaudited)
	Thirteen Weeks Ended						Twenty-Six Weeks Ended
	August 1,			August 2,			August 1,			August 2,
		2026			2025			2026			2025
Net revenues	$	71,649		$	70,858		$	127,351		$	122,510
Cost of sales		28,835			35,361			55,706			64,246
Gross profit		42,814			35,497			71,645			58,264
Selling, general, and administrative expenses		38,747			40,442			72,875			81,246
Other income, net		113			353			762			533
Operating income (loss) from continuing operations		4,180			(4,592	)		(468	)		(22,449	)
Interest income (expense), net		227			(134	)		162			(130	)
Income (loss) from continuing operations before		4,407			(4,726	)		(306	)		(22,579	)
Income tax (benefit) expense		(93	)		(17	)		19			390
Net income (loss) from continuing operations	$	4,500		$	(4,709	)	$	(325	)	$	(22,969	)
Income (loss) from discontinued operations, net of		—			37			—			(15,163	)
Net income (loss)	$	4,500		$	(4,672	)	$	(325	)	$	(38,132	)
Basic weighted-average shares outstanding		28,546			27,935			28,337			27,854
Diluted weighted-average shares outstanding		30,004			27,935			28,337			27,854

Basic net income (loss) per share:
Continuing operations	$	0.16		$	(0.17	)	$	(0.01	)	$	(0.82	)
Discontinued operations	$	—		$	—		$	—		$	(0.55	)
Basic net income (loss) per share	$	0.16		$	(0.17	)	$	(0.01	)	$	(1.37	)
Diluted net income (loss) per share:
Continuing operations	$	0.15		$	(0.17	)	$	(0.01	)	$	(0.82	)
Discontinued operations	$	—		$	—		$	—		$	(0.55	)
Diluted net income (loss) per share	$	0.15		$	(0.17	)	$	(0.01	)	$	(1.37	)

Vera Bradley, Inc. Condensed Consolidated Statements of Cash Flows (in thousands)
(unaudited)
	Twenty-Six Weeks Ended
	August 1,			August 2,
		2026			2025
Cash flows from operating activities
Net loss	$	(325	)	$	(38,132	)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation of property, plant, and equipment		3,522			4,100
Amortization of operating right-of-use assets		9,914			10,220
Impairment charges		—			1,048
Provision for doubtful accounts		161			97
Stock-based compensation		2,658			(29	)
Loss on sale of business		—			15,163
Other non-cash loss, net		92			17
Changes in assets and liabilities:
Accounts receivable		4,321			(3,994	)
Inventories		6,699			(4,913	)
Prepaid expenses and other assets		(1,228	)		(1,212	)
Accounts payable		(1,718	)		2,830
Income taxes		100			140
Operating lease liabilities, net		(11,162	)		(11,772	)
Accrued and other liabilities		4,687			3,139
Net cash provided by (used in) operating activities		17,721			(23,298	)
Cash flows from investing activities
Purchases of property, plant, and equipment		(1,038	)		(2,613	)
Proceeds from sale of business, net of cash disposed		—			1,037
Net cash used in investing activities		(1,038	)		(1,576	)
Cash flows from financing activities
Tax withholdings for equity compensation		(930	)		(200	)
Borrowings under asset-based revolving credit agreement		—			15,000
Repayment of borrowings under asset-based revolving credit agreement		—			(5,000	)
Net cash (used in) provided by financing activities		(930	)		9,800
Effect of exchange rate changes on cash and cash equivalents		(17	)		(108	)
Net increase (decrease) in cash and cash equivalents	$	15,736		$	(15,182	)
Cash and cash equivalents, beginning of period		18,513			30,366
Cash and cash equivalents, end of period	$	34,249		$	15,184

Vera Bradley, Inc. Second Quarter Fiscal 2027 GAAP to Non-GAAP Reconciliation Thirteen Weeks Ended August 1, 2026 (in thousands, except per share amounts)
(unaudited)
		Thirteen Weeks Ended
Net income from continuing operations	$	4,500
Severance(1)		46
Transformation initiatives(1)		30
Income tax adjustments(2)		(1,259	)
Net income from continuing operations – Non-GAAP		3,317
Diluted net loss per share from continuing operations – Non-GAAP	$	0.11

(1) Recorded in selling, general, and administrative (“SG&A”) expenses
(2) Adjusted net income from continuing operations and adjusted diluted EPS are calculated using a statutory tax rate of 26%

	Thirteen Weeks Ended
	Direct		Indirect		Unallocated Corporate Expenses			Total
Operating income (loss) from continuing operations	$	16,682		2,978	$	(15,480	)	$	4,180
Severance		—		—		46			46
Transformation initiatives		3		—		27			30
Operating income (loss) from continuing operations – Non-GAAP	$	16,685	$	2,978	$	(15,407	)	$	4,256

Vera Bradley, Inc. Second Quarter Fiscal 2026 GAAP to Non-GAAP Reconciliation Thirteen Weeks Ended August 2, 2025 (in thousands, except per share amounts)
(unaudited)
		Thirteen Weeks Ended
Net loss from continuing operations	$	(4,709	)
Severance(1)		3,017
Consulting and professional fees(1)		842
Transformation initiatives(1)		276
PO cancellation fees(2)		(126	)
Income tax adjustments(3)		169
Net loss from continuing operations – Non-GAAP		(531	)
Diluted net loss per share from continuing operations – Non-GAAP	$	(0.02	)

(1) Recorded in SG&A expenses
(2) Represents true up of PO cancellation fees and recorded in cost of goods sold
(3) Adjusted net loss from continuing operations and adjusted diluted EPS are calculated using a statutory tax rate of 26%

	Thirteen Weeks Ended
	Direct			Indirect			Unallocated Corporate Expenses			Total
Operating income (loss) from continuing operations	$	9,335			2,190		$	(16,117	)	$	(4,592	)
Severance		—			—			3,017			3,017
Consulting and professional fees		25			—			817			842
Transformation initiatives		15			4			257			276
PO cancellation fees		(108	)		(18	)		—			(126	)
Operating income (loss) from continuing operations – Non-GAAP	$	9,267		$	2,176		$	(12,026	)	$	(583	)

Vera Bradley, Inc. Second Quarter Fiscal 2027 GAAP to Non-GAAP Reconciliation Twenty-Six Weeks Ended August 1, 2026 (in thousands, except per share amounts)
(unaudited)
		Twenty-Six Weeks Ended
Net loss from continuing operations	$	(325	)
Severance(1)		1,163
Consulting and professional fees(1)		27
Professional fees associated with sale of Pura Vida(1)		94
Transformation initiatives(1)		189
Income tax adjustments(2)		(284	)
Net income from continuing operations – Non-GAAP		864
Diluted net income per share from continuing operations – Non-GAAP	$	0.03

(1) Recorded in SG&A expenses
(2) Adjusted net income from continuing operations and adjusted diluted EPS are calculated using a statutory tax rate of 26%

	Twenty-Six Weeks Ended
	Vera Bradley  Direct		Vera Bradley  Indirect		Unallocated  Corporate Expenses			Total
Operating income (loss) from continuing operations	$	19,789		6,987	$	(27,244	)	$	(468	)
Severance		334		117		712			1,163
Consulting and professional fees		—		—		27			27
Professional fees associated with sale of Pura Vida		—		—		94			94
Transformation initiatives		12		2		175			189
Operating income (loss) from continuing operations – Non-GAAP	$	20,135	$	7,106	$	(26,236	)	$	1,005

Vera Bradley, Inc. Second Quarter Fiscal 2026 GAAP to Non-GAAP Reconciliation Twenty-Six Weeks Ended August 2, 2025 (in thousands, except per share amounts)
(unaudited)
	Twenty-Six Weeks Ended
Net loss from continuing operations	$	(22,969	)
Severance(1)		3,307
Consulting and professional fees(2)		1,563
PPE impairment charges(1)		1,048
Professional fees associated with sale of Pura Vida(1)		976
PO cancellation fees(3)		860
Transformation initiatives(1)		276
Inventory write-off associated with sale of Pura Vida(3)		250
Income tax adjustments(4)		4,108
Net loss from continuing operations – Non-GAAP		(10,581	)
Diluted net loss per share from continuing operations – Non-GAAP	$	(0.38	)

(1) Recorded in SG&A expenses
(2) $555 recorded in cost of goods sold and $1,008 recorded in SG&A expenses
(3) Recorded in cost of goods sold
(4) Adjusted net loss from continuing operations and adjusted diluted EPS are calculated using a statutory tax rate of 26%

	Twenty-Six Weeks Ended
	Vera Bradley Direct		Vera Bradley  Indirect		Unallocated Corporate Expenses			Total
Operating income (loss) from continuing operations	$	3,799		4,170	$	(30,418	)	$	(22,449	)
Severance		15		—		3,292			3,307
Consulting and professional fees		608		78		877			1,563
PPE impairment charges		1,048		—		—			1,048
Professional fees associated with sale of Pura Vida		—		—		976			976
PO cancellation fees		739		121		—			860
Transformation initiatives		15		4		257			276
Inventory write-off associated with sale of Pura Vida		214		36		—			250
Operating income (loss) from continuing operations – Non-GAAP	$	6,438	$	4,409	$	(25,016	)	$	(14,169	)

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/c527f37f-2b70-4b61-ae88-6261d9c06282

CONTACT: CONTACTS:
Investors:
Tom Filandro, Partner ICR, Inc
VeraBradleyIR@icrinc.com

Media: VeraBradley@icrinc.com

Experienced biopharmaceutical and nephrology leader joins SCYNEXIS to advance its rare disease development programs

JERSEY CITY, N.J., Sept. 15, 2026 (GLOBE NEWSWIRE) — SCYNEXIS, Inc. (NASDAQ: SCYX) (the Company or SCYNEXIS), a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases, today announced the appointment of Todd Minga, M.D. as Senior Vice President, Research & Development, effective September 14, 2026.

Dr. Minga brings more than two decades of experience spanning clinical medicine, drug development, medical affairs, clinical research, and strategic leadership in kidney disease and rare disorders. He joins SCYNEXIS from Akebia Therapeutics, where he most recently served as Vice President, Medical Affairs and Clinical Development. In that role, he helped shape clinical and regulatory strategies, support pipeline advancement, engage with regulators and key opinion leaders, and contribute to business development initiatives. Prior to Akebia, Dr. Minga held leadership positions at Maze Therapeutics, IQVIA, and practiced as a board-certified nephrologist for more than 16 years.

“Todd is a highly accomplished physician and biopharmaceutical leader whose unique combination of clinical expertise, development leadership, and deep understanding of kidney disease makes him exceptionally well-suited to lead our research and development organization,” said David Angulo, M.D., Chief Executive Officer of SCYNEXIS. “As we advance SCY-770 and SCY-247, Todd’s experience building and executing development strategies will be invaluable. We are delighted to welcome him to the leadership team.”

“I am excited to join SCYNEXIS at this important stage in the Company’s evolution,” said Dr. Minga. “SCYNEXIS has built a differentiated, clinical-stage portfolio focused on addressing severe, progressive and underserved rare diseases. As a nephrologist, the opportunity to help advance SCY-770 for patients with autosomal dominant polycystic kidney disease is especially meaningful to me, given the significant unmet needs that remain. The Company’s antifungal program further demonstrates the depth and breadth of its scientific capabilities. I look forward to working with the SCYNEXIS team to advance these programs and, ultimately, improve outcomes for patients.”

Dr. Minga earned his Doctor of Medicine degree from Eastern Virginia Medical School and completed his residency in Internal Medicine and fellowship in Nephrology at the University of Alabama at Birmingham. He is board certified in Internal Medicine and Nephrology and has authored numerous scientific publications in kidney disease and related therapeutic areas.

In connection with his appointment, on September 14, 2026, Dr. Minga was granted an option to purchase 40,000 shares of SCYNEXIS common stock at a per share exercise price of $4.60, the closing trading price on September 14, 2026, and 5,000 restricted stock units (“RSUs”). The stock option has a ten-year term and vests over four years, with one-fourth of the shares subject to the option vesting on the one-year anniversary of the grant date and the remainder vesting in equal monthly installments over the following thirty-six months, provided Dr. Minga continues to provide service to SCYNEXIS. The RSUs vest in three equal annual installments on September 15, 2027, September 15, 2028, and September 15, 2029, subject to Dr. Minga’s continued service with the Company through each applicable vesting date. The stock option and RSUs were granted pursuant to the SCYNEXIS 2015 Inducement Award Plan as a material inducement to Dr. Minga entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

About SCYNEXIS

SCYNEXIS, Inc. (NASDAQ: SCYX) is a clinical stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases. SCY-770 is being developed for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) and has been granted Orphan Drug designation. SCYNEXIS’s proprietary antifungal platform “fungerps” includes BREXAFEMME® (ibrexafungerp tablets), the first approved representative of this novel class, which has been licensed to GSK, and SCY-247, currently in clinical stages of development. For more information, visit www.scynexis.com.

CONTACT: 
Investor Relations
John Fraunces
LifeSci Advisors
Tel: 917-355-2395
jfraunces@lifesciadvisors.com